Clinical Research Directory
Browse clinical research sites, groups, and studies.
A Real-world Study of the Effectiveness of Angiotensin Receptor-Neprilysin Inhibitor Therapy in Hypertensive Patients in the United Arab Emirates
Sponsor: Novartis Pharmaceuticals
Summary
The aim of this study is to evaluate the real-world effectiveness of ARNi (sacubitril/valsartan) therapy and standard antihypertensive monotherapy in reducing blood pressure in hypertensive patients residing in the United Arab Emirates. Standard antihypertensive monotherapies will include angiotensin-converting enzyme (ACE) inhibitors, angiotensin II receptor blockers (ARBs), and calcium channel blockers (CCBs).
Official title: Real-world Effectiveness of Angiotensin Receptor-Neprilysin Inhibitor (ARNi) Therapy in Lowering Blood Pressure in Hypertensive Patients in the United Arab Emirates
Key Details
Gender
All
Age Range
18 Years - 99 Years
Study Type
OBSERVATIONAL
Enrollment
500
Start Date
2026-04-01
Completion Date
2027-04-18
Last Updated
2026-03-12
Healthy Volunteers
No